Has Paul Drain received payments from drug or device companies?

Yes. Drug and device makers reported $149,233 in general payments to Paul Drain across 63 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paul Drain did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paul Drain come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paul Drain

Infectious Disease · Seattle, WANPI 1942489273

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $107,036 of the $149,233 with a category attached, or 71.7%. 7 manufacturers reported payments, led by Abbott at 33.2% of the total. Reporting peaked in 2023 at $52,532 and has fallen 51.5% since, to $25,468 in 2025. Among infectious disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$149,233in general payments, 2019–2025

Across 63 payments — averaging $2368.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$50K
Orasure Technologies Inc.$41K
Oxford Immunotec USA Inc$27K
AbbVie$10K
Lumiradx, Inc.$8K
Roche Diagnostics International Ltd$7K
plus $7K from 1 others

$1,727,431in research payments, 2019–2025

Across 2 payments — averaging $863,716 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Abbott$1.7M

What the payments were for

Consulting fees$107,03672%
Speaking & faculty fees$23,51516%
Travel & lodging$17,76212%
Food & beverage$9201%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	30	$49,578
Orasure Technologies Inc.	10	$40,529
Oxford Immunotec USA Inc	6	$27,000
AbbVie	3	$9,531
Lumiradx, Inc.	3	$8,315
Roche Diagnostics International Ltd	8	$7,388
Cepheid	3	$6,891

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

T-SPOT.TB8$27,000
InteliSwab$22,500
ID NOW INSTRUMENT$16,230
Alinity$10,223
BINAXNOW MALARIA$1,717
Alinity c$1,400
BINAXNOW COVID-19 AG CARD$750
ALERE BINAXNOW INFLUENZA A & B CARD 2$750

How this compares

$149,233 in reported general payments places this provider in the 95th percentile of 186 infectious disease providers in Washington.

See all infectious disease providers in Washington →

Other infectious disease in Seattle

Warren DingesSeattle$173K
Corey CasperSeattle$115K
Anna WaldSeattle$103K
Jim BoonyaratanakornkitSeattle$62K
Michael BoeckhSeattle$59K
Jason GoldmanSeattle$58K
Connie CelumSeattle$57K
Hyang KimSeattle$51K
Ferric FangSeattle$49K
Heidi CraneSeattle$38K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →